Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2 therapy.

Hanker, L., Hitschold, T., Hesse, T., Grafe, A., Förster, F., Schröder, J., Janssen, J., Reichert, D., Hielscher, C., Greinemann, J., Bórquez, D., Schmidt, M., 2013.

J Clin Oncol 31(suppl; abstr 602). doi:DOI: 10.1200/jco.2013.31.15_suppl.602

Studie: Herceptin-NIS; Indikation: Mammakarzinom; Jahr: 2013; Veranstaltung: ASCO; Journal: Journal of Clinical Oncology

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com